Genome wide association studies (GWAS) have identified the H1 microtubule associated protein tau (MAPT) haplotype single nucleotide polymorphisms as leading common risk variants for Parkinson's disease (PD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Gene expression studies have demonstrated haplotype-specific increases in expression of MAPT exon 3-containing transcripts from the protective H2 allele compared to the H1. The difference in alternative splicing between the haplotypes likely contributes risk or protection in the absence of protein coding variants. Here, we investigate the regulation of MAPT exon 3 alternative splicing by common, risk-associated, non-coding, haplotype-specific single nucleotide polymorphisms (SNPs) through a combination of in silico analysis of the MAPT locus, in vitro gene expression and biochemistry studies. Comparative sequence analysis of whole-locus genomic H1 and H2 MAPT (143 kb) vectors showed they capture over 86% of the MAPT sequence diversity. We generated and expressed haplotype-hybrid H1 and H2 MAPT vectors in a human neuroblastoma cell culture model and demonstrated that a functional SNP rs17651213 near the exon 3 5' splice site regulates exon 3 inclusion in a haplotype-specific manner. Using RNA-electrophoretic mobility shift assays (RNA-EMSA), we showed differential RNA-protein complex formation at the H1 and H2 sequence variants of SNP rs17651213. We further identified candidate trans-acting splicing factors interacting with functional SNP rs17651213 sequences by RNA-protein pull-down experiment and mass spectrometry. Finally, gene knockdown of candidate splice factors identified by mass spectrometry demonstrated a role for hnRNP F and hnRNP Q in the haplotype-specific regulation of exon 3 inclusion. In this study, we have dissected the MAPT locus to identify sequences regulating the allele-specific alternative splicing of exon 3 and provided mechanistic insights into how common non-coding H1/H2 MAPT haplotype-specific SNPs may contribute to the risk/protection of neurodegeneration at a complex genetic locus.

Abstract Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) are the two most common neurodegenerative diseases leading to early onset dementia (< 65 years). Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes cause a proportion of familial early-onset AD (eoAD), while the microtubule-associated protein tau (MAPT) and progranulin (PGRN) mutations have been identified in FTLD patients. Only a few PSEN1 and APP mutations have previously been found in Finnish AD patients, and one MAPT mutation in a FTLD family, while the role of PGRN in Finnish FTLD patients is unknown. Increasing evidence suggests that mitochondrial dysfunction and oxidative stress also play an important role in neurodegenerative diseases. The aim here was to investigate the genetics of eoAD and FTLD in the population of the province of Northern Ostrobothnia, Finland. Sequencing analysis of the APP, PSEN1 and PSEN2 genes was performed to determine whether mutations in these genes could be detected. The MAPT and PGRN genes were analysed in the FTLD patients by sequencing and MAPT haplotypes were determined. The contributions of mtDNA and its maintenance enzymes to eoAD and FTLD were studied by comparing the frequencies of mtDNA haplogroups and their clusters between the patient groups and controls and by screening for the five common POLG1 mutations (T251I, A467T, P587L, W748S, Y955C), two common mtDNA mutations (m.3243A>G, m.8344A>G) and mutations in the PEO1 and ANT1 genes. This is the first report of a significant association between the mtDNA haplogroup cluster IWX and FTLD. The H2 MAPT haplotype was also associated with FTLD in our cohort. No significant differences in the frequencies of the mtDNA haplogroups were observed between the eoAD patients and controls, nor were there any pathogenic mutations detected in the genes analysed. The findings suggest that possession of the mtDNA haplogroup cluster IWX and the H2 MAPT haplotype may be possible risk factors for FTLD in our cohort. The absence of any pathogenic mutations in the MAPT, PGRN, APP or PSEN genes in our series, together with the previous reports of only a few mutations found in this region, supports a minor role for these genes in the aetiology of eoAD and FTLD in Northern Ostrobothnia and indicates that this population may have its own genetic features. There may be other, still unknown genetic factors to be discovered, that explain familial diseases in the region.

Les tauopathies sont des maladies neurodégénératives caractérisées par l’agrégation intracérébrale de protéines tau anormales. Cependant ces maladies sont très hétérogènes sur le plan clinique, anatomopathologique mais aussi biochimique avec l'agrégation de différentes isoformes de protéines tau. De nombreux axes de recherche existent à ce jour afin de mieux comprendre ces maladies incurables. Au cours de cette thèse d'université, nous avons étudié les modifications de l’épigénome qui constituent une piste nouvelle et très prometteuse dans la recherche sur les maladies neurodégénératives. L'épigénétique est un processus dynamique et réversible qui peut être modifié par de nombreux facteurs génétiques ou environnementaux et qui joue un rôle très important dans la régulation des gènes. De nombreuses études rapportent une association entre certaines marques épigénétiques et les maladies neurodégénératives. Par exemple, dans la maladie d’Alzheimer, il a été observé une hyperméthylation de l'ADN, au niveau du promoteur du gène MAPT qui code les protéines tau.Dans ce contexte, nos objectifs étaient de déterminer si des variations de l'épigénome impliquant le gène MAPT contribuent à l'expression différentielle des protéines tau qui est observée dans les différentes classes de tauopathies. Nous avons donc constitué et caractérisé une banque de prélèvements cérébraux de témoins et de patients atteints de différentes tauopathies. Puis nous avons analysé la méthylation de l'ADN dans 3 tauopathies : la maladie d'Alzheimer, la paralysie supranucléaire progressive et la DCB. Notre étude a permis de mettre en évidence chez les patients atteints de PSP une hypométhylation dans l’inton 0 du gène MAPT. Cette hypométhylation ne concernait que le cortex frontal, affecté par la pathologie tau, mais pas le cortex occipital qui est épargné par la pathologie tau. De plus, nous avons également mis en évidence dans le tissu cérébral des patients atteints de PSP une hyperexpression des ARNm de MAPT par rapport aux témoins. Nous démontrons avec ce travail que l’hypométhylation de l'ADN de l’intron 0 de MAPT constitue une signature épigénétique spécifique de la PSP. Cette première étude nous a conduits à suspecter l'existence d'un promoteur alternatif du gène MAPT situé dans cette région de l'intron 0. Nous avons donc testé in vitro l'activité de ce promoteur et cloné des transcrits issu de ce promoteur alternatif. Nous avons ensuite confirmé ces analyses par la mesure de l'expression des ARNm par qPCR. Au total, ces expériences prouvent l'existence et la fonctionnalité de ce promoteur alternatif dans le cerveau humain. De plus, l'activation de ce promoteur alternatif aboutit à la transcription d'ARNm plus courts codant pour de nouvelles protéines tau qui pourraient être impliquées dans la survenue des tauopathies. / Tauopathies are neurodegenerative diseases characterized by intracerebral aggregation of abnormal tau proteins. However, these diseases are heterogeneous clinically, pathologically but also biochemically with the aggregation of different isoforms of tau protein. Many lines of research exist to date to better understand these incurable diseases. During this university thesis, we studied the changes in the epigenome that constitute a new and very promising approach in research on neurodegenerative diseases. Epigenetics is a dynamic and reversible process which can be modified by numerous genetic or environmental factors and plays a very important role in gene regulation. Many studies report an association between some epigenetic marks and neurodegenerative diseases. For example, in Alzheimer\'s disease, it has been observed hypermethylation of DNA in the promoter of the MAPT gene which encodes the tau protein.In this context, our objective was to determine if changes in epigenomic involving MAPT gene contribute to the differential expression of tau protein which is observed in the different classes of tauopathies. So we have established and characterized a human brainbank of controls and patients with different tauopathies. Then we analyzed the DNA methylation in 3 tauopathies: Alzheimer\'s disease, progressive supranuclear palsy, and CBD. Our study highlighted in PSP patients hypomethylation in intron 0 of MAPT gene. This hypomethylation concerned only the frontal cortex, affected by the tau-pathology but not the occipital cortex which is spared by tau-pathology. In addition, we also shown in the brain tissue of patients with PSP an overexpression of mRNA of MAPT compared to controls. We demonstrate in this work that hypomethylation of DNA in intron 0 of MAPT is a specific epigenetic signature of PSP. This first study has led us to suspect the existence of an alternative promoter of the MAPT gene located in this region of intron 0. We tested the in vitro activity of this promoter and cloned transcripts derived from this alternative promoter. We then confirmed this analysis by measuring mRNA expression by qPCR. In total, these experiments prove the existence and the functionality of this alternative promoter in the human brain. Furthermore, activation of the alternative promoter results in shorter mRNA transcripts encoding novel tau proteins that might be involved in the onset of the tauopathies.

Aggregation of microtubule-associated protein tau is involved in the pathology of several neurodegenerative diseases, including Alzheimer’s disease. The affibody TP4 has been shown to inhibit this aggregation process, and its target-binding positions were previously grafted onto a dimeric affibody scaffold, creating the sequestrin seqTP4. This project constitutes a part of the affinity maturation process of seqTP4, using two different bacterial display methods. An error-prone PCR library was first expressed on Staphylococcus carnosus cells for selection of variants with improved tau-binding properties, resulting in a library of 1.4×107 transformants. Flow cytometric tests indicated difficulties in the setup due to nonspecific interactions, and whereas several different approaches to alleviate the problems were investigated, two cell sorting attempts were ultimately unsuccessful. Subcloning of seqTP4 and the library to an Escherichia coli surface display vector resulted in functional surface expression of seqTP4 on E. coli JK321 and BL21 cells, and a BL21 library size of 1.6×109 transformants. An initial flow cytometric test of this library indicates the presence of improved tau-binding variants, paving the way for future cell sorting. / Aggregering av mikrotubuli-associerat protein tau är involverad i patologin av flera neurodegenerativa sjukdomar, däribland Alzheimers sjukdom. Affibodymolekylen TP4 har visat sig inhibera denna aggregeringsprocess, och överföring av dess målbindande positioner till ett dimeriskt affibodyprotein har tidigare gett upphov till seqTP4, en så kallad sequestrin. Detta projekt utgör ett led i processen att affinitetsmaturera seqTP4, med hjälp av två olika metoder för presentation av proteiner på ytan av bakterieceller. Ett error-prone PCR-bibliotek uttrycktes först på ytan av Staphylococcus carnosus-celler för selektion av varianter med ökad affinitet för tau, vilket resulterade i ett bibliotek av 1.4×107 transformanter. Flödescytometriska tester tydde på svårigheter i detta upplägg på grund av ospecifika interaktioner, och emedan flera olika angreppssätt för att förmildra dessa problem undersöktes, misslyckades slutligen två cellsorteringsförsök. Omkloning av seqTP4 och biblioteket till en vektor för ytpresentation på Escherichia coli resulterade i funktionellt ytuttryck av seqTP4 på E. coli JK321- och BL21-celler, och ett BL21-bibliotek bestående av 1.6×109 transformanter. Ett första flödescytometriskt test av detta bibliotek tyder på närvaron av varianter med förbättrad förmåga att binda tau, och vägen ligger nu relativt öppen för cellsortering.

No description available.

AtMAP65-4 est une protéine associée aux microtubules appartenant à la famille des AtMAP65s qui compte 9 membres identifiés chez Arabidopsis thaliana. Ces protéines appartiennent à une famille conservée au cours de l'évolution, les MAP65s. Ainsi, des protéines homologues sont présentes chez de mammifères (PRC1), chez la levure (Ase1p) ou chez la drosophile (FEO). Jusqu'ici l'étude des propriétés moléculaires et fonctionnelles des AtMAP65s s'est portée essentiellement sur l'étude d'AtMAP65-1 et AtMAP65-5. La principale caractéristique de ces protéines est d'induire la formation de faisceaux de microtubules in vitro. La distribution des AtMAP65s in vivo est très régulée, celle-ci sont localisées avec des réseaux des microtubules bien définis. Ainsi, leur rôle supposé est de mettre en place ces réseaux puis de participer à leur maintient. La localisation d'AtMAP65-4 apparait comme très intéressante car elle est strictement associée avec les microtubules du fuseau mitotique. D'après les résultats obtenus au cours de ce travail, nous avons suggéré que la fonction in vivo d'AtMAP65-4 est de participer à la mise en place et au maintient des microtubules en faisceaux dans les fibres kinétochoriennes lors de la division cellulaire. Lors d'une étude in vitro nous avons montré qu'AtMAP65-4 modifie les paramètres dynamiques de polymérisation des microtubules. Outre sa capacité à former des faisceaux, AtMAP65-4 permet une croissance régulière des microtubules au sein des faisceaux qu'elle induit. Le mécanisme d'action de la MAP à l'échelle moléculaire a été analysé à travers une étude bioinformatique où nous avons modélisé l'activité d'AtMAP65-4. Les données obtenues montrent qu'AtMAP65-4 peut bloquer les évènements de dépolymérisation des microtubules. Par ailleurs, l'activité d'AtMAP65-4 pourrait être régulée in vivo par des modifications post traductionnelles. En effet, nous avons montré et étudié l'effet de la phosphorylation d'AtMAP65-4 par les kinases Auroras. Cette phosphorylation pourrait être impliquée dans la régulation de l'activité d'AtMAP65-4 au cours de la mitose. / AtMAP65-4 is a microtubule-associated protein belonging to the AtMAP65s family that comprises 9 members identified in Arabidopsis thaliana. These proteins belong to a family conserved during evolution, MAP65s. Thus, homologous proteins are present in mammals (PRC1), in yeast (Ase1p) or Drosophila (FEO). So far the study of molecular properties and functional AtMAP65s has focused mainly on AtMAP65-1 and AtMAP65-5. The main feature of these proteins is to induce the formation of microtubule bundles in vitro. In vivo, these AtMAP65s are localized with subsets of microtubule bundles as they are suggested to play a role in establishing and maintaining these networks. From the results we obtained on AtMAP65-4 properties during this work such as the in vivo localization, biochemical properties and functional effetc on the MT polymerization, we suggested that the in vivo function of AtMAP65-4 is involved in setting up and maintaining microtubule bundles within kinetochore fibers during cell division. In vitro studies allowed us to show that AtMAP65-4 changes the dynamic parameters of microtubule. In addition to its ability to form bundles, AtMAP65-4 allows steady growth of microtubules in bundles it induces. The mechanism of action of the MAP at the molecular level was analyzed through a bioinformatics study where we modeled the activity of AtMAP65-4 and concluded that it could block the depolymerization events. Moreover, the activity of AtMAP65-4 could be regulated in vivo by post-translational modifications. Indeed, we have shown that AtMAP65-4 is phosphorylated by Aurora kinases in vitro. The effect of this phosphorylation during mitosis is under investigation.

Abstract Frontotemporal lobar degeneration (FTLD) is the second most common neurodegenerative disease leading to early-onset dementia (< 65 years), next to Alzheimer’s disease. FTLD is substantially a genetic disorder with up to 50% of cases having a positive family history. Mutations in the genes microtubule-associated protein tau (MAPT) and progranulin (PGRN) account for about 10–20% of all cases of FTLD. Hexanucleotide repeat expansion mutation within the gene C9ORF72 has recently been identified as the major cause of FTLD, FTLD with amyotrophic lateral sclerosis (ALS) and pure ALS. During this study, hexanucleotide repeat expansion within the C9ORF72 gene was shown to explain nearly 50% of familial and 30% of all FTLD cases in the Finnish population. Otherwise, the genetic background of Finnish FTLD is largely unknown. The object of the present work was to disentangle the genetic aetiology of FTLD in the Finnish population. We studied a cohort of patients with a clinical diagnosis of FTLD from the province of Northern Ostrobothnia, Finland. Sequencing analysis of the genes MAPT, charged multi-vesicular body protein 2B (CHMP2B) and TAR DNA binding protein (TARDBP) were performed and the MAPT haplotypes were analysed. Correlations between genotype and phenotype were studied in patients with C9ORF72 repeat expansion mutation. C9ORF72 expansion mutation explained nearly 30% of cases of FTLD in our cohort. Concomitant ALS and positive family history of the disease increased the possibility of carrying expanded C9ORF72. The clinical phenotype of C9ORF72 expansion carriers varied at presentation: both behavioural and language variants were detected with or without ALS. The behavioural presentations included prominent psychotic features, although psychiatric presentations were not overrepresented in expansion carriers. No pathogenic mutations were identified in the MAPT, CHMP2B and TARDBP genes in our series of FTLD patients. The H2 MAPT haplotype was associated with FTLD in the series. Our findings emphasise the importance of C9ORF72 expansion mutation in FTLD. While mutations in MAPT and PGRN cause a significant proportion of cases of FTLD worldwide, they seem to be rare causes of FTLD in the Finnish population. Besides being infrequent in other populations, mutations in CHMP2B and TARDBP are rare causes of FTLD in the Finnish population as well. Our findings have clinical implications for recognising phenotypic features characteristic of expanded C9ORF72 as well as for genetic counselling of Finnish patients with FTLD. Even though a considerable proportion of our cases of familial FTLD is caused by the C9ORF72 expansion, over 50 % of our familial cases are without a molecular genetic diagnosis, suggesting that there are other unidentified causal genes to be found. / Tiivistelmä Otsa-ohimolohkorappeumat on toiseksi yleisin työikäisten dementiaa aiheuttava etenevä aivojen rappeumasairaus. Toisinaan otsa-ohimolohkorappeumat esiintyvät yhdessä liikehermorappeuman, amyotrofisen lateraaliskleroosin (ALS), kanssa. Perinnöllisillä tekijöillä on todennäköisesti keskeinen merkitys taudin taustalla. Mutaatiot microtubule-associated protein tau (MAPT)- ja progranulin (PGRN) geeneissä aiheuttavat yhteensä 10–20 % otsa-ohimolohkorappeumista maailmalla. C9ORF72-geenissä sijaitsevan toistojaksomonistuman on vastikään todettu olevan yleisin otsa-ohimolohkorappeumia ja ALS:a aiheuttava mutaatio. Mutaatio on erityisen yleinen suomalaisessa väestössä selittäen lähes 50 % suvuittaisista ja 30 % kaikista otsa-ohimolohkorappeumista. Oireyhtymän perinnöllisyys on muutoin huonosti tunnettu suomalaisessa väestössä. Tutkimuksen tavoitteena oli selvittää otsa-ohimolohkorappeumien geneettisiä syitä aineistossa, joka koostui vuosina 1999–2010 Oulun yliopistollisessa sairaalassa tutkituista potilaista. Tutkimuksessa selvitettiin MAPT-, charged multi-vesicular body protein 2B (CHMP2B)- ja TAR DNA-binding protein (TARDBP) geenien mutaatioiden esiintyvyyttä ja määritettiin MAPT-geenin haplotyypit. Lisäksi tutkittiin taudin kliinisiä erityispiirteitä C9ORF72-mutaation kantajilla. C9ORF72-mutaatio selitti lähes 30 % otsa-ohimolohkorappeumista aineistossamme. Tutkimuksessa havaittiin, että suvuittain esiintyvä tautimuoto ja ALS yhdistyneenä otsa-ohimolohkorappeumaan liittyivät merkittävästi C9ORF72-mutaatioon. Monistuman kantajien fenotyyppi oli moninainen – ensioireina oli sekä käytösongelmia että kielellisiä vaikeuksia. Vaikka C9ORF72-mutaation kantajilla on kuvattu runsaasti psykoottisia oireita, psykoottiset oireet eivät olleet selvästi yliedustettuna mutaation kantajilla aineistossamme. Tutkimuksessa ei löydetty tautia aiheuttavia mutaatioita MAPT-, CHMP2B- tai TARDBP-geeneistä. Havaitsimme kuitenkin tilastollisesti merkittävän yhteyden MAPT-geenin H2-haplotyypin ja otsa-ohimolohkorappeumien välillä. Tuloksemme antavat uutta tietoa C9ORF72-mutaation kantajien kliinisistä erityispiirteistä. MAPT-geenin mutaatioiden merkitys otsa-ohimolohkorappeumien synnyssä ei näyttäisi olevan suomalaisessa väestössä niin merkittävä kuin muissa väestöissä. CHMP2B- ja TARDBP-mutaatiot ovat harvinainen oireyhtymän syy myös suomalaisessa väestössä. Tuloksiamme voidaan hyödyntää suomalaisten otsa-ohimolohkorappeumapotilaiden perinnöllisessä neuvonnassa. Huomattavista edistysaskelista huolimatta yli puolet suvuittain esiintyvistä tautitapauksistamme on vailla geneettistä diagnoosia, mikä antaa aihetta jatkotutkimuksille.

No description available.